Insights
Insights From Our Experts
Articles
Supporting Successful Commercialization With Integrated Compliance
Compliance is an integral part of the entire biopharma, medical device and product lifecycle, yet it poses one of the biggest challenges for our customers. While they try to focus on driving value, innovation and patient…
The 10-Year Test: Is It Possible to Plan Launch During Clinical Development?
Time and strategy are keys to launching in an overwhelmed, unpredictable market. Pharmaceutical companies in mid-development of a drug need to look ahead at their launch strategy options and consider what market conditions could look like by the time they’re ready to commercialize their product. By evaluating the value…
Insights From Dreamforce 2020 Panel: End-To-End Patient Engagement
EVERSANA was proud to participate in this year’s brand-new session “End-To-End Patient Engagement: From Clinical Trials Through Patient Support Programs.“ Bhaskar Sambasivan, Chief Strategy Officer and President of Patient Services, provided valuable insight into the emerging…
COVID-19 Vaccine Safety Briefing Report
Posted by Lisa Rinker, Nina Patel Lahanis, Shraddha Bhange, MD, MBBS, Msc. on December 9, 202012/9/20
As the world awaits the fast-approaching rollout of an approved COVID-19 vaccine, developing the planning to order, distribute and track COVID-19 vaccines in the United States and globally presents an unprecedented challenge. The Food and Drug…
What Happens After a COVID-19 Vaccine Trial Succeeds? 4 Pharmacovigilance Challenges to Address During Commercialization
As pharma companies continue to develop COVID-19 vaccines around the world, they are faced with these questions: What happens when we succeed? How will we quickly and safely distribute the vaccine globally? Pulling off this rapid,…
Case Study: Early-Stage Asset Valuation
The rewards of developing a new drug can be very attractive but they come with inherent risks. It is important to ensure that investment decisions on clinical development are made after examining the risk profile of…
How Artificial Intelligence Is Transforming Pharma
From drug discovery to clinical trials to commercialization, artificial intelligence (AI) and machine learning (ML) technologies are transforming the pharma and life sciences industries. Industry leaders who recognize the potential of AI and ML are now…
NORD 2020 Insights: Entering a New Era
EVERSANA was a proud sponsor of the 2020 NORD Rare Diseases & Orphan Products Breakthrough Summit to advance the dialogue on ways to improve the lives of over 25 million Americans living with rare diseases. Our…
Compliance – The Competitive Differentiator to Commercialization: An Integrated Model Setting the New Global Standard
Posted by Vikram Anand, Brandyn Abbott, Emily Becker, Nina Patel Lahanis, Larry Davis, PharmD, Carolyn Quon, PharmD, Lisa Rinker, Thomas Barton on October 1, 202010/1/20
The Compliance experts at EVERSANA prove how integrated life science compliance has earned its seat at the table by demonstrating the value of increasing data-driven and technology-infused competitiveness in the successful commercialization of a new-age biopharma…
Doing the Right Things Right: A Perspective on Rare Disease Drug Development
Millions of patients with rare diseases have benefited from the emphasis biopharmaceutical companies have put on the development of orphan drugs over the last decades. The more patients served, the more complex and challenging it becomes,…